Loading...
 
Register Log In Login with facebook

Dermatologists are reminded of the importance of vitamin D in 8 diseases – Oct 2017

Vitamin D and the Skin: An Update for Dermatologists

American Journal of Clinical Dermatology, pp 1–13
Elio Kechichian, Khaled Ezzedine

Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Patients with photosensitive disorders tend to avoid sun exposure, and this practice, along with photoprotection, can put this category of patients at risk for vitamin D deficiency.
Maintaining a vitamin D serum concentration within normal levels is warranted in

  1. atopic dermatitis,
  2. psoriasis,
  3. vitiligo,
  4. polymorphous light eruption,
  5. mycosis fungoides,
  6. alopecia areata,
  7. systemic lupus erythematosus, and
  8. melanoma patients.

The potential determinants of vitamin D status, as well as the benefits and risks of vitamin D (with a special focus on the skin), will be discussed in this article.

Publisher wants $50 for the PDF

See also VitaminDWiki
  • Skin category listing has 65 items along with related searches
  • Psorasis category listing has 43 items along with related searches
  • Lupus category listing has 49 items along with related searches
  • Cancer – Skin category listing has 94 items along with related searches

References (Some specific diseases are bolded)

1.
Wharton B, Bishop N. Rickets. The Lancet. 2003;362:1389–400.
2.
Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr. 2005;94:483–92.
3.
Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome “X”? Br J Nutr. 1998;79:315–27.
4.
Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol. 2005;81:1276–86.
5.
Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sørensen OH. Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr. 2001;86(Suppl 1):S97–103.
6.
Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005;330:120.
7.
Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology. 1993;12:1–5.
8.
Burris HH, Rifas-Shiman SL, Huh SY, Kleinman K, Litonjua AA, Oken E, et al. Vitamin D status and hypertensive disorders in pregnancy. Ann Epidemiol. 2014;24(399–403):e1.
9.
Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165:1246–52.
10.
Chan TY. Vitamin D deficiency and susceptibility to tuberculosis. Calcif Tissue Int. 2000;66:476–8.
11.
Bellamy R. Evidence of gene-environment interaction in development of tuberculosis. The Lancet. 2000;355:588–9.
12.
Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230–3.
13.
Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89:552–72.
14.
Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78:1463–70.
15.
Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007;16:618–25.
16.
Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. Exp Dermatol. 2004;13(Suppl 4):11–5.
17.
Chen TC, Chimeh F, Lu Z, Mathieu J, Person KS, Zhang A, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys. 2007;460:213–7.
18.
Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–64.
19.
Lucas RM, Gorman S, Geldenhuys S, Hart PH. Vitamin D and immunity. F1000Prime Rep. 2014;6:118.
20.
Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev. 2008;66:S153–64.
21.
Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85:860–8.
22.
Rice SA, Carpenter M, Fityan A, Vearncombe LM, Ardern-Jones M, Jackson AA, et al. Limited exposure to ambient ultraviolet radiation and 25-hydroxyvitamin D levels: a systematic review. Br J Dermatol. 2015;172:652–61.
23.
Cusack C, Danby C, Fallon JC, Ho WL, Murray B, Brady J, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008;24:260–7.
24.
Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. Determinants of vitamin D status in Caucasian adults: influence of sun exposure, dietary intake, sociodemographic, lifestyle, anthropometric, and genetic factors. J Invest Dermatol. 2015;135:378–88.
25.
Gillie O. A new government policy is needed for sunlight and vitamin D. Br J Dermatol. 2006;154:1052–61.
26.
Major JM, Graubard BI, Dodd KW, Iwan A, Alexander BH, Linet MS, et al. Variability and reproducibility of circulating vitamin D in a nationwide U.S. population. J Clin Endocrinol Metab. 2013;98:97–104.
27.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
28.
Ezzedine K, Mauger E, Latreille J, Jdid R, Malvy D, Gruber F, et al. Freckles and solar lentigines have different risk factors in Caucasian women. J Eur Acad Dermatol Venereol. 2013;27:e345–56.
29.
Ezzedine K, Malvy D, Mauger E, Nageotte O, Galan P, Hercberg S, et al. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults. J Eur Acad Dermatol Venereol. 2008;22(2):186–94.
30.
Felton SJ, Cooke MS, Kift R, Berry JL, Webb AR, Lam PMW, et al. Concurrent beneficial (vitamin D production) and hazardous (cutaneous DNA damage) impact of repeated low-level summer sunlight exposures. Br J Dermatol. 2016;175:1320–8.
31.
Terushkin V, Bender A, Psaty EL, Engelsen O, Wang SQ, Halpern AC. Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. J Am Acad Dermatol. 2010;62:929.e1–9.
32.
Wacker M, Holick MF. Sunlight and vitamin D: a global perspective for health. Dermatoendocrinology. 2013;5:51–108.
33.
Rapuri PB, Gallagher JC, Haynatzki G. Effect of vitamins D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcif Tissue Int. 2004;74:150–6.
34.
Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.
35.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.
36.
Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch Intern Med. 2009;169:551.
37.
Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One. 2014;9:e111265.
38.
Hintzpeter B, Mensink GBM, Thierfelder W, Müller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008;62:1079–89.
39.
Mithal A, Wahl DA, Bonjour J-P, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–20.
40.
Carrillo-Vega MF, García-Peña C, Gutiérrez-Robledo LM, Pérez-Zepeda MU. Vitamin D deficiency in older adults and its associated factors: a cross-sectional analysis of the Mexican Health and Aging Study. Arch Osteoporos. 2017;12:8.
41.
Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidiroglou N, Sarafin K, et al. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int. 2011;22:1389–99.
42.
Daly RM, Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Sikaris KA, et al. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf). 2012;77:26–35.
43.
Bertrand KA, Giovannucci E, Liu Y, Malspeis S, Eliassen AH, Wu K, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr. 2012;108:1889–96.
44.
Thuesen B, Husemoen L, Fenger M, Jakobsen J, Schwarz P, Toft U, et al. Determinants of vitamin D status in a general population of Danish adults. Bone. 2012;50:605–10.
45.
Engelman CD, Meyers KJ, Iyengar SK, Liu Z, Karki CK, Igo RP, et al. Vitamin D intake and season modify the effects of the GC and CYP2R1 genes on 25-hydroxyvitamin D concentrations. J Nutr. 2013;143:17–26.
46.
Berger C, Greene-Finestone LS, Langsetmo L, Kreiger N, Joseph L, Kovacs CS, et al. Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res. 2012;27:1381–9.
47.
Kimlin MG, Lucas RM, Harrison SL, Van Der Mei I, Armstrong BK, Whiteman DC, et al. The contributions of solar ultraviolet radiation exposure and other determinants to serum 25-hydroxyvitamin D concentrations in Australian adults: The AusD study. Am J Epidemiol. 2014;179:864–74.
48.
Bjørneboe GE, Johnsen J, Bjørneboe A, Rousseau B, Pedersen JI, Norum KR, et al. Effect of alcohol consumption on serum concentration of 25-hydroxyvitamin D3, retinol, and retinol-binding protein. Am J Clin Nutr. 1986;44:678–82.
49.
Shirazi L, Almquist M, Malm J, Wirfält E, Manjer J. Determinants of serum levels of vitamin D: a study of life-style, menopausal status, dietary intake, serum calcium, and PTH. BMC Women Health. 2013;13:33.
50.
Lee K. Sex-specific relationships between alcohol consumption and vitamin D levels: the Korea National Health and Nutrition Examination Survey 2009. Nutr Res Pract. 2012;6:86–90.
51.
Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet. 2010;376:180–8.
52.
Hiraki LT, Major JM, Chen C, Cornelis MC, Hunter DJ, Rimm EB, et al. Exploring the genetic architecture of circulating 25-hydroxyvitamin D. Genet Epidemiol. 2013;37:92–8.
53.
Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J. Steroid Biochem. Mol. Biol. 2014;144 Pt A:132–7.
54.
Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991–2000.
55.
McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr. 2009;29:111–32.
56.
Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19:2739–45.
l57.
Trummer O, Schwetz V, Walter-Finell D, Lerchbaum E, Renner W, Gugatschka M, et al. Allelic determinants of vitamin d insufficiency, bone mineral density, and bone fractures. J Clin Endocrinol Metab. 2012;97:E1234–40.
58.
Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr. 1998;67:1232–6.
59.
Young AR. Some light on the photobiology of vitamin D. J Invest Dermatol. 2010;130:346–8.
60.
Xiang F, Lucas R, de Gruijl F, Norval M. A systematic review of the influence of skin pigmentation on changes in the concentrations of vitamin D and 25-hydroxyvitamin D in plasma/serum following experimental UV irradiation. Photochem Photobiol Sci. 2015;14:2138–46.
61.
Batai K, Murphy AB, Shah E, Ruden M, Newsome J, Agate S, et al. Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet. 2014;133:1395–405.
62.
Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol. 2008;159:211–3.
63.
Mukamel MN, Weisman Y, Somech R, Eisenberg Z, Landman J, Shapira I, et al. Vitamin D deficiency and insufficiency in orthodox and non-orthodox Jewish mothers in Israel. Isr Med Assoc J. 2001;3:419–21.
64.
Allali F, El Aichaoui S, Saoud B, Maaroufi H, Abouqal R, Hajjaj-Hassouni N. The impact of clothing style on bone mineral density among post menopausal women in Morocco: a case–control study. BMC Public Health. 2006;6:135.
65.
Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case–control study. Br J Dermatol. 2009;161(Suppl 3):78–84.
66.
Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91:526–9.
67.
Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: six years’ experience with xeroderma pigmentosum. J Am Acad Dermatol. 1997;37:942–7.
68.
Querings K, Reichrath J. A plea for the analysis of vitamin-D levels in patients under photoprotection, including patients with xeroderma pigmentosum (XP) and basal cell nevus syndrome (BCNS). Cancer Causes Control. 2004;15:219.
69.
Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64:1165–8.
70.
Marks R, Foley PA, Jolley D, Knight KR, Harrison J, Thompson SC. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol. 1995;131:415–21.
71.
Farrerons J, Barnadas M, López-Navidad A, Renau A, Rodríguez J, Yoldi B, et al. Sunscreen and risk of osteoporosis in the elderly: a two-year follow-up. Dermatology. 2001;202:27–30.
72.
Kannan S, Lim HW. Photoprotection and vitamin D: a review. Photodermatol Photoimmunol Photomed. 2014;30:137–45.
73.
Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol. 2009;161:732–6.
74.
Vähävihu K, Ala-Houhala M, Peric M, Karisola P, Kautiainen H, Hasan T, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol. 2010;163:321–8.
75.
Romaní J, Caixàs A, Carrascosa JM, Ribera M, Rigla M, Luelmo J. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol. 2012;166:1237–44.
76.
Ryan C, Moran B, McKenna MJ, Murray BF, Brady J, Collins P, et al. The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. Arch Dermatol. 2010;146:836–42.
77.
Feldmeyer L, Shojaati G, Spanaus K-S, Navarini A, Theler B, Donghi D, et al. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. J Am Acad Dermatol. 2013;69:530–6.
78.
Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in Vitiligo patients treated with NBUVB therapy. ISRN Dermatol. 2014;2014:493213.
79.
Gruber-Wackernagel A, Obermayer-Pietsch B, Byrne SN, Wolf P. Patients with polymorphic light eruption have decreased serum levels of 25-hydroxyvitamin-D3 that increase upon 311 nm UVB photohardening. Photochem Photobiol Sci. 2012;11:1831–6.
80.
Barth J, Gerlach B, Knuschke P, Lehmann B. Serum 25(OH)D3 and ultraviolet exposure of residents in an old people’s home in Germany. Photodermatol Photoimmunol Photomed 1992–1993;9:229–31.
81.
Karppinen T, Ala-Houhala M, Ylianttila L, Kautiainen H, Viljakainen H, Reunala T, et al. Narrowband ultraviolet B exposures maintain vitamin D levels during winter: a randomized controlled trial. Acta Derm Venereol. 2016;96:490–3.
82.
Bogh MKB, Gullstrand J, Svensson A, Ljunggren B, Dorkhan M. Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D3 per day: a randomized clinical trial. Br J Dermatol. 2012;167:625–30.
83.
Tostmann A, Wielders JPM, Kibiki GS, Verhoef H, Boeree MJ, van der Ven AJAM. Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. Int J Tuberc Lung Dis. 2010;14:1147–52.
84.
Joosse A, Koomen ER, Casparie MK, Herings RMC, Guchelaar H-J, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case–control study. J Invest Dermatol. 2009;129:2620–7.
85.
Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89.
86.
Maghzi H, Ataei B, Khorvash F, Yaran M, Maghzi A-H. Association between acute infectious mononucleosis and vitamin D deficiency. Viral Immunol. 2016;29:398–400.
87.
Albenali LH, Danby S, Moustafa M, Brown K, Chittock J, Shackley F, et al. Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: a pilot study. J Allergy Clin Immunol. 2016;138(1715–1719):e4.
88.
Abhimanyu A, Coussens AK. The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. Photochem Photobiol Sci. 2017;16:314–38.
89.
Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97:3951–9.
90.
Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest. 2007;117:1988–94.
91.
Neville F, Cahuzac M, Konovalov O, Ishitsuka Y, Lee KYC, Kuzmenko I, et al. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J. 2006;90:1275–87.
92.
Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA. 2006;103:1516–21.
93.
Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011;6:e25333.
94.
Campbell GR, Spector SA. Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem. 2011;286:18890–902.
95.
Muehleisen B, Bikle DD, Aguilera C, Burton DW, Sen GL, Deftos LJ, et al. PTH/PTHrP and vitamin D control antimicrobial peptide expression and susceptibility to bacterial skin infection. Sci Transl Med. 2012;4:135.
96.
Kota S, Sabbah A, Chang TH, Harnack R, Xiang Y, Meng X, et al. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem. 2008;283:22417–29.
97.
Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2000;17:F39–48.
98.
Heine G, Hoefer N, Franke A, Nöthling U, Schumann RR, Hamann L, et al. Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. Br J Dermatol. 2013;168:855–8.
99.
Kılıç S, Sılan F, Hız M, Işık S, Ögretmen Z, Özdemir Ö. Vitamin D receptor gene BSMI, FOKI, APAI, and TAQI polymorphisms and the risk of atopic dermatitis. J Investig Allergol Clin Immunol. 2016;26:106–10.
100.
Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016;387:1109–22.
101.
Hata TR, Kotol P, Boguniewicz M, Taylor P, Paik A, Jackson M, et al. History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163:659–61.
102.
Camargo CA, Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol. 2014;134(831–835):e1.
103.
Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J, et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:781–9.
104.
Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662–87.
105.
Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54:383–92.
106.
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi:10.1016/S0140-6736(14)60763-7.
107.
Cho S, Kim J, Cho S, Park J, Park Y, Oh S. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25:64–7.
108.
Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2016;32:181–90.
109.
Ezzedine K, Whitton M, Pinart M. Interventions for Vitiligo. JAMA. 2016;316:1708.
110.
Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price H, et al. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61:1387–95.
111.
Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012;21:36–42.
112.
Amital H, Szekanecz Z, Szücs G, Dankó K, Nagy E, Csépány T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7.
113.
Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep. 2008;10:273–80.
114.
Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013;55:10–21.
115.
Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1569–74.
116.
Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A, et al. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clin Rheumatol. 2017;36:583–90.
117.
Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011;347:90–6.
PubMedPubMedCentra
l118.
Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol. 2014;170:1299–304.
119.
Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology. 2011;134:123–39.
120.
Ersoy-Evans S. Commentary: vitamin D and autoimmunity: is there an association? J Am Acad Dermatol. 2010;62:942–4.
121.
Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16:S25–7.
122.
Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, et al. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012;24:341–4.
123.
Çerman AA, Solak SS, Altunay İ, Küçükünal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14:616–20.
124.
Gruber-Wackernagel A, Bambach I, Legat FJ, Hofer A, Byrne SN, Quehenberger F, et al. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D3 analogue in polymorphic light eruption. Br J Dermatol. 2011;165:152–63.
125.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
126.
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.
127.
Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. The Lancet. 2007;369:1603–13.
128.
Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case–control study. J Invest Dermatol. 2011;131:1460–8.
129.
Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by l α,25-dihydroxyvitamin D3. Endocrinology. 1983;113:1950–7.
130.
Bikle DD, Gee E, Pillai S. Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J Invest Dermatol. 1993;101:713–8.
131.
Ellison TI, Smith MK, Gilliam AC, MacDonald PN. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J Invest Dermatol. 2008;128:2508–17.
132.
Carless MA, Kraska T, Lintell N, Neale RE, Green AC, Griffiths LR. Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. Br J Dermatol. 2008;159:804–10.
133.
Moll PR, Sander V, Frischauf A-M, Richter K. Expression profiling of vitamin D treated primary human keratinocytes. J Cell Biochem. 2007;100:574–92.
134.
Wong G, Gupta R, Dixon KM, Deo SS, Choong SM, Halliday GM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Bio. 2004;89–90:567–70.
135.
De Haes P, Garmyn M, Verstuyf A, De Clercq P, Vandewalle M, Degreef H, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B Biol. 2005;78:141–8.
136.
Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gärtner BC, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Investig. 2004;84:693–702.
137.
Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006;4:e232.
138.
Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, et al. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch. Dermatol. 2011;147:1379.
139.
Asgari MM, Tang J, Warton ME, Chren M-M, Quesenberry CP, Bikle D, et al. Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. J Invest Dermatol. 2010;130:1438–43.
140.
Tang JY, Parimi N, Wu A, John Boscardin W, Shikany JM, Chren M-M, et al. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control. 2010;21:387–91.
141.
Park SM, Li T, Wu S, Li W-Q, Qureshi AA, Cho E. Vitamin D intake and risk of skin cancer in US women and men. PLoS One. 2016;11:e0160308.
142.
Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, et al. Vitamin D Deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014;14:518–24.
143.
Rasheed H, Hegazy RA, Gawdat HI, Mehaney DA, Kamel MM, Fawzy MM, et al. Serum vitamin D and vitamin D receptor gene polymorphism in mycosis fungoides patients: a case–control study. PLoS One. 2016;11:e0158014.
144.
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798–812.
145.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.
146.
Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159:105–12.
147.
Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer. 2012;130:405–18.
148.
Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-Dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982;42:856–9.
149.
Reichrath J, Rafi L, Rech M, Meineke V, Tilgen W, Seifert M. No evidence for amplification of 25-hydroxyvitamin d-1α-OHase (1α-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM). J Steroid Biochem Mol Biol. 2004;89–90:163–6.
150.
Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med. 1999;133:120–8.
151.
Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang Y-M, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27:5439–44.
152.
Newton-Bishop JA, Davies JR, Latheef F, Randerson-Moor J, Chan M, Gascoyne J, et al. 25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. Int J Cancer. 2015;136:2890–9.
153.
Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res. 2009;29:3669–74.
154.
Davies JR, Field S, Randerson-Moor J, Harland M, Kumar R, Anic GM, et al. An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res. 2014;27:234–43.
155.
Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, et al. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 2016;37:30–8.
156.
Field S, Davies J, Bishop DT, Newton-Bishop JA. Vitamin D and melanoma. Dermatoendocrinology. 2013;5:121–9.
157.
Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009;45:3271–81.
158.
Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1042–51.
159.
Veierød MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer. 1997;71:600–4.
160.
Miller SA, Coelho SG, Yamaguchi Y, Hearing VJ, Beer JZ, de Gruijl F. The evaluation of non-invasive measurements of erythema as a potential surrogate for DNA damage in repetitively UV-exposed human skin. Photochem Photobiol. 2017;93:1282–8.
161.
Petersen B, Wulf HC, Triguero-Mas M, Philipsen PA, Thieden E, Olsen P, et al. Sun and ski holidays improve vitamin D status, but are associated with high levels of DNA damage. J Invest Dermatol. 2014;134:2806–13.
162.
Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res. 2007;22(Suppl 2):V64–8.
163.
Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684–96.
164.
Helzlsouer KJ; VDPP Steering Committee. Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:4–9.
165.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.
166.
Bergler-Czop B, Brzezińska-Wcisło L. Serum vitamin D level: the effect on the clinical course of psoriasis. Adv Dermatol Allergol. 2016;6:445–9.
167.
Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis: summary of a cochrane systematic review. Br J Dermatol. 2017;176:604–14.

Created by admin. Last Modification: Wednesday October 11, 2017 13:57:04 UTC by admin. (Version 3)
See any problem with this page? Report it to the webmaster.